28 November 2023
28 November 2023
Companies plan to submit the supplemental data on Dupixent to the US Food and Drug Administration (FDA) by the end of 2023.
Boehringer will utilise a generative AI model developed by IBM to discover candidate antibodies.
The monoclonal antibody, approved to treat certain B-cell lymphomas, has received an FDA breakthrough therapy designation.
A decision on the approval from the regulator is anticipated on 15 July 2024.
The vaccine can induce antibodies against the receptor binding domain of the novel coronavirus’ spike protein.
Autolus Theraputics is forging ahead with its T-cell cancer therapy, obe-cel, aimed at treating persistant adult ALL.
Olvi-Vec is currently being evaluated in a Phase III trial as a treatment for platinum- resistant/refractory ovarian cancer.
Mocravimod is currently being investigated in a global Phase III study in AML patients undergoing haematopoietic stem cell transplantation.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Give your business an edge with our leading industry insights.
